BMO Capital analyst Tom MacKinnon lowered the firm’s price target on IGM Financial (IGIFF) to C$47 from C$48 and keeps a Market Perform rating on the shares. Published first on TheFly – the ...

Late Thursday, Aimia announced Tom Finke has resigned as executive ... viability of management’s new strategic focus.” BMO Capital Markets analyst Thanos Moschopoulos lowered his target ...

In her placement year at Central Saint Martins she wangled an internship in New York with the influential Vogue fashion editor Camilla Nickerson through Tom ... at BMO Capital Markets, says ...

Some, including Tom Simons, an economist at Jefferies ... a rates strategist at BMO Capital Markets, in written commentary shared with MarketWatch earlier. Some have even warned that Trump ...

saw an upgrade in their stock rating by BMO Capital Markets, moving from Market Perform to Outperform, while maintaining a price target of Cdn$64.00. The upgrade follows the completion of Capital ...

Fintel reports that on April 6, 2025, CIBC CAPITAL MARKETS downgraded their outlook for Bank of Montreal (NYSE:BMO) from Outperform to Neutral. Analyst Price Forecast Suggests 23.73% Upside As of ...

Shares of AEP opened at $105.53 on Monday. American Electric Power has a 12 month low of $83.68 and a 12 month high of $110.48. The stock has a fifty day moving average price of $104.94 and a 200 ...

Aritzia (TSE:ATZ – Get Free Report) had its price objective lowered by investment analysts at BMO Capital Markets from C$80.00 to C$74.00 in a report issued on Thursday,BayStreet.CA reports.

Tuesday, shares of Capital Power Corp (TSX:CPX:CN) (OTC:CPXWF) saw an upgrade in their stock rating by BMO Capital Markets, moving from Market Perform to Outperform, while maintaining a price target ...

The mounting uncertainty has now prompted BMO Capital Markets to lower its year-end target for the benchmark index. “We are revising our 2025 year-end S&P 500 price targets down to 6,100 from 6,700.

Investing.com -- BMO Capital Markets downgraded Novo Nordisk (NYSE:NVO) to “Market Perform” from “Outperform” and cut its price target to $64, saying the Danish drugmaker’s early lead in ...